218 related articles for article (PubMed ID: 24723174)
1. Risk of pancreatitis in patients treated with incretin-based therapies.
Meier JJ; Nauck MA
Diabetologia; 2014 Jul; 57(7):1320-4. PubMed ID: 24723174
[TBL] [Abstract][Full Text] [Related]
2. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA
Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
5. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
6. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
Lando HM; Alattar M; Dua AP
Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
[TBL] [Abstract][Full Text] [Related]
7. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
8. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.
Wilhite K; Reid JM; Lane M
Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914
[TBL] [Abstract][Full Text] [Related]
9. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
10. Incretin-mimetic therapies and pancreatic disease: a review of observational data.
Suarez EA; Koro CE; Christian JB; Spector AD; Araujo AB; Abraham S
Curr Med Res Opin; 2014 Dec; 30(12):2471-81. PubMed ID: 25180611
[TBL] [Abstract][Full Text] [Related]
11. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
12. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
[TBL] [Abstract][Full Text] [Related]
13. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
Singh AK; Gangopadhyay KK; Singh R
Expert Rev Clin Pharmacol; 2020 Apr; 13(4):461-468. PubMed ID: 32129106
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
15. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
16. GLP-1-based therapies: the dilemma of uncertainty.
Spranger J; Gundert-Remy U; Stammschulte T
Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
[No Abstract] [Full Text] [Related]
17. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based therapies: facing the realities of benefits versus side effects.
Lebovitz HE
Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
[No Abstract] [Full Text] [Related]
19. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
20. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
